Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
about
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Correction: Mutant JAK3 phosph ...... l acute lymphoblastic leukemia
@en
type
label
Correction: Mutant JAK3 phosph ...... l acute lymphoblastic leukemia
@en
prefLabel
Correction: Mutant JAK3 phosph ...... l acute lymphoblastic leukemia
@en
P2093
P1433
P1476
Correction: Mutant JAK3 phosph ...... l acute lymphoblastic leukemia
@en
P2093
C E de Bock
H C Murray
I Govaerts
N M Verrills
P Van Vlierberghe
S Bornschein
P356
10.1038/S41375-018-0241-7
P577
2018-12-01T00:00:00Z